In a pivotal phase II trial involving patients with previously treated recurrent or metastatic cervical cancer, cadonilimab achieved an ORR of 33.0%, including a complete response rate of 12.0%; notably, the ORR reached 43.8% among PD-L1–positive patients (23). This evidence concerns the gene CD274 and cervical cancer.